Pleiotropic effects of apolipoprotein A-Ⅱ on high-density lipoprotein functionality, adipose tissue metabolic activity and plasma glucose homeostasis

Zvintzou Evangelia; Xepapadaki Eva; Kalogeropoulou Christina; Filou Serafoula; Kypreos Kyriakos E.

doi:10.7555/JBR.33.20190048

Volume 34 Issue 1

Jan. 2020

Turn off MathJax

Article Contents

Abstract

References

The Journal of Biomedical Research > 2020 > 34(1): 14-26. > DOI: 10.7555/JBR.33.20190048

Zvintzou Evangelia, Xepapadaki Eva, Kalogeropoulou Christina, Filou Serafoula, Kypreos Kyriakos E.. Pleiotropic effects of apolipoprotein A-Ⅱ on high-density lipoprotein functionality, adipose tissue metabolic activity and plasma glucose homeostasis[J]. The Journal of Biomedical Research, 2020, 34(1): 14-26. DOI: 10.7555/JBR.33.20190048

Citation:

PDF (1831 KB)

Pleiotropic effects of apolipoprotein A-Ⅱ on high-density lipoprotein functionality, adipose tissue metabolic activity and plasma glucose homeostasis

Department of Pharmacology, University of Patras Medical School, Rio Achaias, TK 26500, Greece

More Information

Corresponding author:
Kyriakos E. Kypreos, Department of Pharmacology, University of Patras Medical School, Panepistimioupolis, Rio Achaias, TK 26500, Greece. Tel/ Fax: +302610969120/+302610996103, E-mail: kkypreos@med.upatras.gr
Received Date: March 28, 2019
Revised Date: May 13, 2019
Accepted Date: May 15, 2019
Available Online: July 25, 2019

Graphical Abstract

Abstract

Abstract

Apolipoprotein A-Ⅱ (APOA-Ⅱ) is the second most abundant apolipoprotein of high-density lipoprotein (HDL) synthesized mainly by the liver and to a much lesser extent by the intestine. Transgenic mice overexpressing human APOA-Ⅱ present abnormal lipoprotein composition and are prone to atherosclerosis, though in humans the role for APOA-Ⅱ in coronary heart disease remains controversial. Here, we investigated the effects of overexpressed APOA-Ⅱ on HDL structure and function, adipose tissue metabolic activity, glucose tolerance and insulin sensitivity. C57BL/6 mice were infected with an adenovirus expressing human APOA-Ⅱ or a control adenovirus AdGFP, and five days post-infection blood and tissue samples were isolated. APOA-Ⅱ expression resulted in distinct changes in HDL apoproteome that correlated with increased antioxidant and anti-inflammatory activities. No effects on cholesterol efflux from RAW 264.7 macrophages were observed. Molecular analyses in white adipose tissue (WAT) indicated a stimulation of oxidative phosphorylation coupled with respiration for ATP production in mice overexpressing APOA-Ⅱ. Finally, overexpressed APOA-Ⅱ improved glucose tolerance of mice but had no effect on the response to exogenously administered insulin. In summary, expression of APOA-Ⅱ in C57BL/6 mice results in pleiotropic effects with respect to HDL functionality, adipose tissue metabolism and glucose utilization, many of which are beneficial to health.
- apolipoprotein A-Ⅱ,
- high-density lipoprotein,
- adipose tissue,
- glucose tolerance,
- insulin sensitivity

FullText(HTML)

References (35)

References

[1]	Brewer HB Jr, Lux SE, Ronan R, et al. Amino acid sequence of human apoLp-Gln-Ⅱ (apoA-Ⅱ), an apolipoprotein isolated from the high-density lipoprotein complex[J]. Proc Natl Acad Sci USA, 1972, 69(5): 1304–1308. doi: 10.1073/pnas.69.5.1304
[2]	Pownall HJ, Gillard BK, Gotto AM Jr. Setting the course for apoAⅡ: a port in sight?[J]. Clin Lipidol, 2013, 8(5): 551–560. doi: 10.2217/clp.13.59
[3]	Borghini I, Barja F, Pometta D, et al. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid[J]. Biochim Biophys Acta, 1995, 1255(2): 192–200. doi: 10.1016/0005-2760(94)00232-N
[4]	Warden CH, Hedrick CC, Qiao JH, et al. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-Ⅱ[J]. Science, 1993, 261(5120): 469–472. doi: 10.1126/science.8332912
[5]	van't Hooft FM, Ruotolo G, Boquist S, et al. Human evidence that the apolipoprotein A-Ⅱ gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins[J]. Circulation, 2001, 104(11): 1223–1228. doi: 10.1161/hc3601.095709
[6]	Gordon SM, Chung JH, Playford MP, et al. High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography[J]. Atherosclerosis, 2018, 278: 278–285. doi: 10.1016/j.atherosclerosis.2018.09.032
[7]	Constantinou C, Karavia EA, Xepapadaki E, et al. Advances in high-density lipoprotein physiology: surprises, overturns, and promises[J]. Am J Physiol Endocrinol Metab, 2016, 310(1): E1–E14. doi: 10.1152/ajpendo.00429.2015
[8]	Tsompanidi EM, Brinkmeier MS, Fotiadou EH, et al. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis[J]. Atherosclerosis, 2010, 208(1): 3–9. doi: 10.1016/j.atherosclerosis.2009.05.034
[9]	Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events[J]. N Engl J Med, 2007, 357(21): 2109–2122. doi: 10.1056/NEJMoa0706628
[10]	Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 367(22): 2089–2099. doi: 10.1056/NEJMoa1206797
[11]	Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease[J]. N Engl J Med, 2017, 376(20): 1933–1942. doi: 10.1056/NEJMoa1609581
[12]	The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med, 2011, 365(24): 2255–2267. doi: 10.1056/NEJMoa1107579
[13]	The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med, 2014, 371(3): 203–212. doi: 10.1056/NEJMoa1300955
[14]	Bowe B, Xie Y, Xian H, et al. High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. Veterans[J]. Clin J Am Soc Nephrol, 2016, 11(10): 1784–1793. doi: 10.2215/CJN.00730116
[15]	Loscalzo J. Molecular mechanisms of atherosclerosis[M]. London: CRC Press, 2004: 111–174.
[16]	Kavo AE, Rallidis LS, Sakellaropoulos GC, et al. Qualitative characteristics of HDL in young patients of an acute myocardial infarction[J]. Atherosclerosis, 2012, 220(1): 257–264. doi: 10.1016/j.atherosclerosis.2011.10.017
[17]	Filou S, Lhomme M, Karavia EA, et al. Distinct roles of apolipoproteins A1 and E in the modulation of high-density lipoprotein composition and function[J]. Biochemistry, 2016, 55(27): 3752–3762. doi: 10.1021/acs.biochem.6b00389
[18]	Zvintzou E, Lhomme M, Chasapi S, et al. Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity[J]. J Lipid Res, 2017, 58(9): 1869–1883. doi: 10.1194/jlr.M077925
[19]	Pamir N, Pan C, Plubell DL, et al. Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity[J]. J Lipid Res, 2019, 60(3): 594–608. doi: 10.1194/jlr.M090555
[20]	Kontush A, Lindahl M, Lhomme M, et al. Structure of HDL: particle subclasses and molecular components[M]//von Eckardstein A, Kardassis D. High density lipoproteins. Cham: Springer, 2015: 3–51.
[21]	Boyce G, Button E, Soo S, et al. The pleiotropic vasoprotective functions of high density lipoproteins (HDL)[J]. J Biomed Res, 2018, 32(3): 164–182.
[22]	Kypreos KE. ABCA1 promotes the de novo biogenesis of apolipoprotein CⅢ-containing HDL particles in vivo and modulates the severity of apolipoprotein CⅢ-induced hypertriglyceridemia[J]. Biochemistry, 2008, 47(39): 10491–10502. doi: 10.1021/bi801249c
[23]	Constantinou C, Mpatsoulis D, Natsos A, et al. The low density lipoprotein receptor modulates the effects of hypogonadism on diet-induced obesity and related metabolic perturbations[J]. J Lipid Res, 2014, 55(7): 1434–1447. doi: 10.1194/jlr.M050047
[24]	Tselepis AD, Dentan C, Karabina SAP, et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme[J]. Arterioscler Thromb Vasc Biol, 1995, 15(10): 1764–1773. doi: 10.1161/01.ATV.15.10.1764
[25]	Kelesidis T, Currier JS, Huynh D, et al. A biochemical fluorometric method for assessing the oxidative properties of HDL[J]. J Lipid Res, 2011, 52(12): 2341–2351. doi: 10.1194/jlr.D018937
[26]	Knott TJ, Priestley LM, Urdea M, et al. Isolation and characterisation of a cDNA encoding the precursor for human apolipoprotein AⅡ[J]. Biochem Biophys Res Commun, 1984, 120(3): 734–740. doi: 10.1016/S0006-291X(84)80168-0
[27]	Petropoulou PI, Berbée JFP, Theodoropoulos V, et al. Lack of LCAT reduces the LPS-neutralizing capacity of HDL and enhances LPS-induced inflammation in mice[J]. Biochim Biophys Acta, 2015, 1852(10): 2106–2115. doi: 10.1016/j.bbadis.2015.07.010
[28]	Rensen PCN, van Berkel TJC. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo[J]. J Biol Chem, 1996, 271(25): 14791–14799. doi: 10.1074/jbc.271.25.14791
[29]	Larsson M, Allan CM, Jung RS, et al. Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL[J]. J Lipid Res, 2017, 58(9): 1893–1902. doi: 10.1194/jlr.M078220
[30]	Kypreos KE, Van Dijk KW, Havekes LM, et al. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia[J]. J Biol Chem, 2005, 280(8): 6276–6284. doi: 10.1074/jbc.M413458200
[31]	Julve J, Escolà-Gil JC, Rotllan N, et al. Human apolipoprotein A-Ⅱ determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome[J]. Arterioscler Thromb Vasc Biol, 2010, 30(2): 232–238. doi: 10.1161/ATVBAHA.109.198226
[32]	Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, et al. Functional lecithin: cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-Ⅱ[J]. J Biol Chem, 1996, 271(12): 6720–6728. doi: 10.1074/jbc.271.12.6720
[33]	Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2[J]. J Lipid Res, 2012, 53(9): 1767–1782. doi: 10.1194/jlr.R024190
[34]	Flachs P, Rossmeisl M, Kuda O, et al. Stimulation of mitochondrial oxidative capacity in white fat independent of UCP1: a key to lean phenotype[J]. Biochim Biophys Acta, 2013, 1831(5): 986–1003. doi: 10.1016/j.bbalip.2013.02.003
[35]	Castellani LW, Goto AM, Lusis AJ. Studies with apolipoprotein A-Ⅱ transgenic mice indicate a role for HDLs in adiposity and insulin resistance[J]. Diabetes, 2001, 50(3): 643–651. doi: 10.2337/diabetes.50.3.643

[1]	Tiwari-Heckler Shilpa, Jiang Z. Gordon, Popov Yury, J. Mukamal Kenneth. Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study[J]. The Journal of Biomedical Research, 2020, 34(2): 139-142. DOI: 10.7555/JBR.33.20190041
[2]	Tao Chun'ai, Gan Yongxin, Su Weidong, Li Zhutian, Tang Xiaolan. Effectiveness of hospital disinfection and experience learnt from 11 years of surveillance[J]. The Journal of Biomedical Research, 2019, 33(6): 408-413. DOI: 10.7555/JBR.33.20180118
[3]	Huan Liu, Shijiang Zhang, Yongfeng Shao, Xiaohu Lu, Weidong Gu, Buqing Ni, Qun Gu, Junjie Du. Biomechanical characterization of a novel ring connector for sutureless aortic anastomosis[J]. The Journal of Biomedical Research, 2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
[4]	Minbo Zang, Qiao Zhou, Yunfei Zhu, Mingxi Liu, Zuomin Zhou. Effects of chemotherapeutic agent bendamustine for nonhodgkin lymphoma on spermatogenesis in mice[J]. The Journal of Biomedical Research, 2018, 32(6): 442-453. DOI: 10.7555/JBR.31.20170023
[5]	Kaibo Lin, Shikun Zhang, Jieli Chen, Ding Yang, Mengyi Zhu, Eugene Yujun Xu. Generation and functional characterization of a conditional Pumilio2 null allele[J]. The Journal of Biomedical Research, 2018, 32(6): 434-441. DOI: 10.7555/JBR.32.20170117
[6]	Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
[7]	Fengzhen Wang, Mingwan Zhang, Dongsheng Zhang, Yuan Huang, Li Chen, Sunmin Jiang, Kun Shi, Rui Li. Preparation, optimization, and characterization of chitosancoated solid lipid nanoparticles for ocular drug delivery[J]. The Journal of Biomedical Research, 2018, 32(6): 411-423. DOI: 10.7555/JBR.32.20160170
[8]	Christopher J. Danford, Zemin Yao, Z. Gordon Jiang. Non-alcoholic fatty liver disease: a narrative review of genetics[J]. The Journal of Biomedical Research, 2018, 32(6): 389-400. DOI: 10.7555/JBR.32.20180045
[9]	Yong Ji, Mingfeng Zheng, Shugao Ye, Jingyu Chen, Yijiang Chen. PTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer[J]. The Journal of Biomedical Research, 2014, 28(6): 462-467. DOI: 10.7555/JBR.27.20130084
[10]	Xiaodong Yang, Ping Huang, Feng Wang, Zekuan Xu, Xiaonin Wang. Growth hormone receptor expression in human primary gastric adenocarcinoma[J]. The Journal of Biomedical Research, 2012, 26(5): 307-314. DOI: 10.7555/JBR.26.20110133

Cited By

Cited by

Periodical cited type(1)

Tazesh S, Tamizi E, Siahi Shadbad M, et al. Comparative Stability of Two Anti-hyperpigmentation Agents: Kojic Acid as a Natural Metabolite and Its Di-Palmitate Ester, Under Oxidative Stress; Application to Pharmaceutical Formulation Design. Adv Pharm Bull, 2022, 12(2): 329-335. DOI:10.34172/apb.2022.031

Other cited types(0)

Get Citation

PDF

XML

Article Metrics

Article views (4988) PDF downloads (143) Cited by(1)

CiteScore

Impact Factor

Pleiotropic effects of apolipoprotein A-Ⅱ on high-density lipoprotein functionality, adipose tissue metabolic activity and plasma glucose homeostasis